163 related articles for article (PubMed ID: 33954981)
1. Rare and fatal complication of immune checkpoint inhibition: a case report of haemophagocytic lymphohistiocytosis with severe lichenoid dermatitis.
Choi S; Zhou M; Bahrani E; Martin BA; Ganjoo KN; Zaba LC
Br J Haematol; 2021 Jun; 193(6):e44-e47. PubMed ID: 33954981
[No Abstract] [Full Text] [Related]
2. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
Marques-Piubelli ML; Tetzlaff MT; Nagarajan P; Duke TC; Glitza Oliva IC; Ledesma DA; Aung PP; Torres-Cabala CA; Wistuba II; Prieto VG; Nelson KC; Curry JL
J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
[TBL] [Abstract][Full Text] [Related]
3. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review.
Dupré A; Michot JM; Schoeffler A; Frumholtz L; Baroudjian B; Delyon J; Lebbe C; Lambotte O
Br J Haematol; 2020 Jun; 189(5):985-992. PubMed ID: 32243578
[No Abstract] [Full Text] [Related]
4. Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report.
Esfahani K; Henderson Berg MH; Zargham H; Billick R; Pehr K; Redpath M; Roshdy O; Miller WH
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771890
[TBL] [Abstract][Full Text] [Related]
5. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
Tetzlaff MT; Nagarajan P; Chon S; Huen A; Diab A; Omar P; Aung PP; Torres-Cabala CA; Mays SR; Prieto VG; Curry JL
Am J Dermatopathol; 2017 Feb; 39(2):121-129. PubMed ID: 28134729
[TBL] [Abstract][Full Text] [Related]
6. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
[TBL] [Abstract][Full Text] [Related]
7. Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors.
Kurozumi A; Takahashi H; Watanabe T; Iwasaki Y
Thorac Cancer; 2021 May; 12(10):1625-1628. PubMed ID: 33783978
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
Shi VJ; Rodic N; Gettinger S; Leventhal JS; Neckman JP; Girardi M; Bosenberg M; Choi JN
JAMA Dermatol; 2016 Oct; 152(10):1128-1136. PubMed ID: 27411054
[TBL] [Abstract][Full Text] [Related]
9. Granulomatous and lichenoid dermatitis after IgG4 anti-PD-1 monoclonal antibody therapy for advanced cancer.
Diaz-Perez JA; Beveridge MG; Victor TA; Cibull TL
J Cutan Pathol; 2018 Jun; 45(6):434-438. PubMed ID: 29468713
[TBL] [Abstract][Full Text] [Related]
10. Association of Hemophagocytic Lymphohistiocytosis and Programmed Death 1 Checkpoint Inhibitors.
Laderian B; Koehn K; Holman C; Lyckholm L; Furqan M
J Thorac Oncol; 2019 Apr; 14(4):e77-e78. PubMed ID: 30922584
[No Abstract] [Full Text] [Related]
11. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
Ellis SR; Vierra AT; Millsop JW; Lacouture ME; Kiuru M
J Am Acad Dermatol; 2020 Oct; 83(4):1130-1143. PubMed ID: 32360716
[TBL] [Abstract][Full Text] [Related]
12. Interstitial granulomatous dermatitis and granulomatous arteritis in the setting of PD-1 inhibitor therapy for metastatic melanoma.
Singh P; Wolfe SP; Alloo A; Gottesman SP
J Cutan Pathol; 2020 Jan; 47(1):65-69. PubMed ID: 31390071
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.
Schaberg KB; Novoa RA; Wakelee HA; Kim J; Cheung C; Srinivas S; Kwong BY
J Cutan Pathol; 2016 Apr; 43(4):339-46. PubMed ID: 26762844
[TBL] [Abstract][Full Text] [Related]
14. PD-1 blockader-associated atypical hemophagocytic lymphohistiocytosis: A cautionary case report.
He L; Zhuang Y; Zhang D; Tang Z
Transfus Apher Sci; 2023 Apr; 62(2):103603. PubMed ID: 36470726
[TBL] [Abstract][Full Text] [Related]
15. Clinical characterization of hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors: a review of published cases.
Xu Z; Li H; Yu X; Luo J; Zhang Z
Hematology; 2024 Dec; 29(1):2340144. PubMed ID: 38606818
[TBL] [Abstract][Full Text] [Related]
16. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features.
Tetzlaff MT; Tang S; Duke T; Grabell DA; Cabanillas ME; Zuo Z; Yao JC; Nagarajan P; Aung PP; Torres-Cabala CA; Duvic M; Prieto VG; Huen A; Curry JL
J Cutan Pathol; 2019 Nov; 46(11):872-877. PubMed ID: 31254410
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitor-induced lichenoid drug eruption-sparing scar burns.
Truong K; Chamberlin CV; Kim J; Carlino MS; Araujo RR
Australas J Dermatol; 2024 Mar; 65(2):163-166. PubMed ID: 38009870
[TBL] [Abstract][Full Text] [Related]
18. Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab.
Chou S; Hwang SJ; Carlos G; Wakade D; Fernandez-Penas P
Am J Dermatopathol; 2017 Jan; 39(1):23-27. PubMed ID: 28045749
[TBL] [Abstract][Full Text] [Related]
19. Pravastatin-induced lichenoid drug eruption.
Pua VS; Scolyer RA; Barnetson RS
Australas J Dermatol; 2006 Feb; 47(1):57-9. PubMed ID: 16405486
[TBL] [Abstract][Full Text] [Related]
20. Histopathologically-confirmed lichenoid eruptions from immune checkpoint inhibitor therapy: a retrospective cohort analysis.
Jacoby TV; Chang MS; Thompson LL; Foreman RK; Reynolds KL; Chen ST
Br J Dermatol; 2021 Dec; 185(6):1254-1256. PubMed ID: 34375436
[No Abstract] [Full Text] [Related]
[Next] [New Search]